Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 22-year-old woman is evaluated in the intensive care unit for ongoing management of acetaminophen toxicity. She presented to the emergency department 4 hours after an intentional ingestion of an unknown quantity of acetaminophen, at which time her serum acetaminophen level was 180 µg/mL. She was promptly started on a standard 21-hour intravenous N-acetylcysteine (NAC) protocol. She is currently asymptomatic, denies nausea or abdominal pain, and is tolerating oral intake. She is currently at the 20th hour of the NAC infusion.

Laboratory results drawn 1 hour ago (at hour 19 of the infusion) show:

Laboratory TestCurrent ResultAdmission Result
Acetaminophen< 10 µg/mL180 µg/mL
Aspartate aminotransferase (AST)850 U/L45 U/L
Alanine aminotransferase (ALT)920 U/L50 U/L
Total bilirubin1.1 mg/dL0.8 mg/dL
INR1.11.0
Creatinine0.8 mg/dL0.8 mg/dL

Which of the following is the most appropriate next step in management?

  1. Continue intravenous N-acetylcysteine at the current maintenance rateCevap
  2. B
    Discontinue intravenous N-acetylcysteine and transition to oral N-acetylcysteine
  3. C
    Discontinue intravenous N-acetylcysteine and recheck transaminases in 12 hours
  4. D
    Consult hepatology for urgent liver transplantation evaluation
  5. E
    Administer fresh frozen plasma and continue intravenous N-acetylcysteine

Cevap

Continue intravenous N-acetylcysteine at the current maintenance rate
The decision to discontinue N-acetylcysteine (NAC) therapy following the standard 21-hour intravenous protocol requires all of the following criteria to be met: the patient must be clinically asymptomatic, the serum acetaminophen concentration must be undetectable, the INR must be less than 1.5, and the serum transaminases (AST and ALT) must be normal or clearly trending downward. Although this patient's acetaminophen level is undetectable and her INR is normal, her transaminases have increased significantly since admission and have not yet demonstrated a downward trend. Therefore, the NAC infusion must be continued at the maintenance rate (6.25 mg/kg/hr) beyond the initial 21 hours. The infusion should be maintained, and laboratory values should be rechecked every 12 hours until the transaminases peak and begin to definitively decline.

Adım Adım Çözüm

1
Evaluate the patient's current clinical status and laboratory parameters against the established stopping criteria for the 21-hour intravenous N-acetylcysteine (NAC) protocol.
The patient is asymptomatic, has an undetectable acetaminophen level, and a normal INR. However, her transaminases (AST and ALT) have risen significantly since admission and have not yet peaked or demonstrated a downward trend.
Stopping NAC prematurely in the setting of ongoing active liver injury can lead to fulminant hepatic failure.
2
Determine the appropriate management modification for a patient who does not meet all criteria to discontinue NAC.
The correct action is to continue the continuous maintenance infusion of IV NAC.
Guidelines mandate that the maintenance rate (6.25 mg/kg/hr) be continued continuously until all stopping criteria (including down-trending transaminases) are met.

Anahtar Kavram

Evaluation of criteria for discontinuing N-acetylcysteine therapy in acetaminophen toxicity
Bu soruyu puanla